Oxford Biomedica PLC said it signed a new license and supply agreement for its lentiviral vector delivery platform LentiVector with US biotech company Cabaletta Bio, Inc.
The agreement gives Cabaletta Bio a non-exclusive license to LentiVector for its application in the US company’s leading Chimeric AutoAntibody Receptor (CAAR) T programme, DSG3-CAART (targeting DSG3), and puts in place a multi-year supply agreement, Oxford Biomedica said in a statement.
Cabaletta Bio is developing engineered T cells designed to treat patients with autoimmune diseases.
Oxford Biomedica said the financial arrangements of the agreement are in line with comparable deals it previously secured.
Cabaletta Bio’s DSG3-CAART is being evaluated in the DesCAARTes Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris (mPV), a prototypical B cell-mediated autoimmune disease.
The licence and supply agreement also allows for the parties to initiate additional projects in the future.
Oxford Biomedica chief executive John Dawson said: "Cabaletta Bio is one of the leading companies developing engineered T cells designed to treat patients with autoimmune diseases. We are delighted to announce this new collaboration which strengthens our portfolio of relationships with leaders in the gene-modified cell therapy field."